There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Lexaria Bioscience (LEXX – Research Report), Evolus (EOLS – Research Report) and Inspire Medical Systems (INSP – Research Report) with bullish sentiments.
Lexaria Bioscience (LEXX)
Maxim Group analyst Michael Okunewitch maintained a Buy rating on Lexaria Bioscience on January 17. The company’s shares closed last Monday at $1.52.
According to TipRanks.com, Okunewitch has 0 stars on 0-5 stars ranking scale with an average return of
The the analyst consensus on Lexaria Bioscience is currently a Moderate Buy rating.
See today’s best-performing stocks on TipRanks >>
Evolus (EOLS)
Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on Evolus on January 17 and set a price target of $23.00. The company’s shares closed last Monday at $12.13, close to its 52-week high of $12.81.
According to TipRanks.com, Samimy is a 4-star analyst with an average return of
Evolus has an analyst consensus of Strong Buy, with a price target consensus of $23.00, representing a 91.7% upside. In a report issued on January 17, Needham also maintained a Buy rating on the stock with a $22.00 price target.
Inspire Medical Systems (INSP)
In a report issued on January 17, Adam Maeder from Piper Sandler assigned a Buy rating to Inspire Medical Systems, with a price target of $250.00. The company’s shares closed last Monday at $208.11.
According to TipRanks.com, Maeder is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Inspire Medical Systems with a $263.45 average price target, implying a 30.1% upside from current levels. In a report issued on January 19, Jefferies also initiated coverage with a Buy rating on the stock with a $245.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LEXX:
- Lexaria Bioscience unveils planned 2024 GLP-1 study program
- Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream
- Lexaria Bioscience announces availability of broadcast on GLP-1
- Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform
- Lexaria Bioscience announces final results from human pilot study of DehydraTECH
